-
Abdera in connection with its US$110-million combined series A and B financing
-
Neovasc in connection with its acquisition by Shockwave for approximately US$100-million
-
Alpha-9 Theranostics in connection with its US$75-million series B financing
-
Zymeworks in connection with its plan of arrangement transaction to become a Delaware corporation
-
The underwriters in connection with the US$20-million public offering of units by Medicenna Therapeutics
-
NervGen Pharma in connection with its US$15.23-million private placement of units
-
Xenon Pharmaceuticals in connection with its US$287.5-million public offering of common shares
-
Incisive Genetics in connection with its C$12-million seed financing
-
Eupraxia Pharmaceuticals in connection with its C$14.7-million overnight marketed public offering of units
-
Zymeworks in connection with its US$115-million public offering of common shares
-
Trillium Therapeutics in connection with its acquisition by Pfizer for US$2.22-billion
-
Ouest Business Solutions in connection with its acquisition by Deloitte
-
Xenon Pharma in connection with its US$345-million public offering of common shares
-
Boreal Genomics in connection with its acquisition by Natera
-
iCo Therapeutics in connection with its reverse take-over transaction by Satellos Bioscience
-
Complex Biotech Discovery Ventures in connection with its acquisition by Delic Labs
-
Terry Fox Research Institute in connection with the establishment of the Digital Health and Discovery Platform
-
Alpha-9 Theranostics in connection with its US$11-million series A financing
-
NewGen Therapeutics in connection with its TSXV qualifying transaction with Rakovina Therapeutics
-
Vivifi Biotech, an affiliate of Parkinson's UK, in connection with its acquisition of certain assets of MedGenesis Therapeutics
-
Tevosol in connection with its acquisition by Bridge to Life
-
Essa Pharma in connection with its US$150-million public offering of common shares
-
Eupraxia in connection with its C$41-million initial public offering of common shares and warrants on the Toronto Stock Exchange
-
Xenon Pharmaceuticals in connection with its US$115-million public offering of common shares
-
Neovasc in connection with its US$72-million MJDS registered direct offering of common shares
-
Notch Therapeutics in connection with its US$85-million series A financing
-
adMare BioInnovations in connection with the C$20-million launch of FORUS Therapeutics
-
adMare BioInnovations in connection with the C$8-million seed financing of Abdera Therapeutics
-
A syndicate of agents in connection with the C$24.2-million private placement of subscription receipts issued by Sustainable Produce Urban Delivery
-
AbCellera Biologics in connection with its US$555.5-million initial public offering of common shares on NASDAQ
-
The underwriters in connection with the up to US$25-million at-the-market offerings of common shares by Medicenna Therapeutics
-
Novoheart in connection with its going private transaction
-
Neovasc in connection with its US$6.1-million MJDS registered direct offering of common shares
-
NervGen in connection with its C$6.45-million public offering of units
-
Neovasc in connection with its US$12.6-million MJDS registered direct offering of common shares
-
ESSA Pharma in connection with its US$49-million public offering of common shares
-
Neoleukin Therapeutics in connection with the sale of its subsidiary, Aquinox Pharma, to Taro Pharmaceutical
-
Neovasc in connection with its US$11.5-million MJDS registered direct offering of units
-
Correvio Pharma in connection with its acquisition by ADVANZ Pharma for US$76-million
-
Essa Pharma in connection with its up to US$35-million at-the-market common share offering
-
Xenon Pharmaceuticals in connection with its US$69-million public offering of common shares
-
Zymeworks in connection with its US$320.8-million public offering of common shares and pre-funded warrants
-
adMare BioInnovations in connection with its business combination with Accel-Rx
-
Neovasc in connection with its US$10-million MJDS registered direct offering of units
-
Zymeworks in connection with its US$75-million at-the-market common share offering
-
Xenon Pharmaceuticals in connection with its US$50-million at-the-market common share offering
-
ESSA in connection with its US$36-million public offering of common shares and pre-funded warrants
-
Zymeworks in connection with its US$201.3-million cross border prospectus offering of common shares
-
Centre for Drug Research and Development in connection with its business combination with NEOMED Institute to create adMare BioInnovations
-
Novoheart in connection with its acquisition of Xellera Therapeutics
-
ESSA Pharma in connection with its acquisition of Realm Therapeutics
-
The underwriters in connection with the US$350-million private placement of 5.25% convertible senior notes due 2024 by Aphria
-
Jones Brown in connection with its sale to Arthur J. Gallagher & Co.
-
Helius Medical in connection with its US$20.1-million MJDS prospectus offering of common shares
-
Jam City in connection with the acquisition of Bingo Pop from Uken Games
-
Xenon Pharmaceuticals in connection with its US$63-million prospectus offering of common shares
-
Zymeworks in connection with its US$97.8-million MJDS prospectus offering of common shares
-
Anandia Laboratories in connection with its acquisition by Aurora Cannabis for C$115-million in common shares
-
Cardiome Pharma in connection with the acquisition of its Canadian business portfolio by Cipher Pharmaceuticals for C$25.5-million pursuant to a statutory plan of arrangement
-
Helius Medical in connection with its US$14.1-million prospectus offering of common shares and warrants and its concurrent listing on the NASDAQ Global Select Market
-
Seaspan in connection with its US$500-million private placements of 5.50% debentures and warrants to Fairfax Financial Holdings
-
ESSA in connection with its US$26-million prospectus offering and concurrent private placement of common shares and pre-funded warrants
-
Neovasc in connection with its US$37.5-million underwritten offering of series A and series B units (comprised of a combination of common shares or series D pre-funded warrants, series C units and series A, B, C and F warrants to purchase common shares) and concurrent US$27.8-million private placement of notes and series E warrants to purchase common shares
-
The underwriters in connection with the C$11.5-million prospectus offering of units by Oncolytics Biotech
-
Zymeworks in connection with its US$64-million initial public offering of common shares and listing on the Toronto Stock Exchange and the New York Stock Exchange
-
Helius Medical in connection with its C$12.5-million MJDS prospectus offering of common shares
-
Trilogy International in connection with its US$875-million business combination with Alignvest Acquisition Corporation, a special purpose acquisition corporation (SPAC)
-
Volkswagen Financial Services AG in connection with its acquisition of PayByPhone
-
Neovasc in connection with the sale of its tissue business and concurrent private placement to Boston Scientific for US$75-million
-
Weyerhaeuser in connection with the sale of its Cellulose Fibers pulp mill in Alberta to International Paper
-
Response Biomedical in connection with its going-private transaction
-
ESSA in connection with its US$10-million term loan from Silicon Valley Bank
-
The underwriters in connection with the US$25.9-million prospectus offering of common shares by Xenon Pharmaceuticals and the concurrent US$8.6-million secondary offering
-
3D Signatures in connection with the closing of its qualifying transaction on the TSX Venture Exchange and concurrent C$5.45-million private placement of common shares
-
The underwriters in connection with the exchange offer of DFC Finance's US$800-million outstanding principal amount of 10.5% senior secured notes due in 2020
-
Opko Health in connection with its acquisition of Transition Therapeutics for US$60-million in common shares
-
Cardiome Pharma in connection with its US$34.5-million MJDS prospectus offering of common shares
-
SciVac in connection with its acquisition of VBI Vaccines for US$92.1-million in shares
-
Helius Medical in connection with its C$10.2-million prospectus offering and its listing on the Toronto Stock Exchange
-
Private company in connection with its US$25-million series C preferred share financing
-
ESSA Pharma in connection with its US$15-million private placement of units
-
Zymeworks in connection with its US$61.5-million mezzanine preferred share financing
-
Zymeworks in connection with its equity investment and optional merger agreement with Kairos Therapeutics
-
Cardiome Pharma in connection with its up to US$20-million prospectus offering
-
CPI Card Group in connection with its US$150-million initial public offering of common shares, concurrent US$22.5-million secondary offering, and listing on the Toronto Stock Exchange and NASDAQ Global Select Market
-
Cardiome Pharma in connection with its US$23-million prospectus offering of common shares
-
VRG Capital in connection with its backing of a management buy-out of Jones Brown, and the subsequent acquisition of Pearson Dunn Insurance
-
UrtheCast in connection with the C$100-million acquisition of the Earth Observation business of Elecnor and its concurrent prospectus offering of C$100-million of subscription receipts
-
SciVac in connection with its reverse take-over transaction of Levon Resources with an aggregate transaction value of C$356-million and its listing on the Toronto Stock Exchange
-
The underwriters in connection with the US$55.2-million prospectus offering of common shares by Trillium Therapeutics
-
Urthecast in connection with its C$17.25-million prospectus offering of common shares
-
Neovasc in connection with its US$74.9-million MJDS prospectus offering of common shares and the concurrent US$11.9-million secondary prospectus offering
-
Zymeworks in connection with its C$27-million private placement and the expansion of its strategic collaboration with Eli Lilly and Company
-
The underwriters in connection with the US$41.4-million initial public offering of common shares by Xenon Pharmaceuticals and its listing on the NASDAQ Global Select Market
-
Neovasc in connection with its C$25-million prospectus offering of common shares
-
The underwriters in connection with the US$60-million prospectus offering of common shares by Tekmira Pharmaceuticals
-
The underwriters in connection with the US$53-million initial public offering of common shares by Aquinox Pharmaceuticals and its listing on the NASDAQ Global Select Market
-
Cardiome Pharma in connection with its C$15-million prospectus offering of common shares and the concurrent C$15-million secondary prospectus offering
-
Cardiome Pharma in connection with its C$30-million at-the-market prospectus offering of common shares
-
The agent in connection with the US$52-million private placement of units of Aurinia Pharmaceuticals
-
Aequus Pharmaceuticals in connection with its private placement, prospectus filing and direct listing on the TSX Venture Exchange
-
ESSA Pharma in connection with its private placement, prospectus filing and direct listing on the TSX Venture Exchange
-
iCo Therapeutics in connection with its C$6.75-million prospectus offering of common shares
-
UrtheCast in connection with its C$10-million prospectus offering of common shares
-
Cardiome Pharma in connection with its cross-border acquisition of Correvio
-
Response Biomedical in connection with its private placement of subscription receipts
-
GenomeDx Biosciences in connection with its series B preferred share financing
-
Boreal Genomics in connection with its series C preferred share financing
-
UrtheCast in connection with its reverse takeover transaction of Longford Energy, concurrent financing and listing on the Toronto Stock Exchange
-
enGene in connection with its series A preferred share financing
-
Aspreva Pharmaceuticals in connection with its acquisition by Galenica for US$950-million
-
ID Biomedical in connection with its acquisition by GlaxoSmithKline for C$1.7-billion